A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Type of Cancer
Solid Tumor

Phase

Division (Location)

Study ID

NCT#

Brief Description
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.